Sensifai emerges from stealth with a landmark peer-reviewed study in The Lancet Digital Health, validating its world-first AI platform to detect inflammatory events before symptoms, redefining how and when care begins.

Micrologic is embarking on a new chapter of growth after raising $45 million in a funding round backed by the Fonds de solidarité FTQ and Investissement Québec.

Fondaction and the Business Development Bank of Canada have invested in Icentia, a Québec medical technology company. The funding round, which included existing investors Investissement Québec, CIC Capital, and the Theodorus Fund, will accelerate deployment of Icentia's CardioSTAT® technology. CardioSTAT® is a long-term ambulatory cardiac monitoring solution combining a single-use ECG recorder with artificial intelligence-powered analysis. The technology enables early detection of cardiac arrhythmias, helping prevent complications as heart disease becomes more prevalent. The investment comes as Icentia reaches financial and operational self-sufficiency, supported by commercial traction across several key markets. Icentia operates cardiac diagnostic facilities in Canada, the United Kingdom, and the United States. Fondaction manages more than $4.5 billion in net assets as of 31 May 2026.